OCT 10, 2017 09:00 AM PDT

WEBINAR: Automated single cell dissociation of primary tumors and patient-derived xenografts

SPONSORED BY: Miltenyi Biotec
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Assistant Laboratory Member, Memorial Sloan Kettering Cancer Center Medicine
    Biography
      My lab focuses on development of new patient derived xenograft models and experimental lung cancer therapeutics. During my career I have developed a wide range of skills in both laboratory based and computational research. My hybrid skill set positions me well to operate at the interface between the world of the wet lab and that of the high-performance computing cluster. My research has focused on the genetic and epigenetic landscapes of small cell lung cancer, therapeutic targeting of the DLL3, and development of oncolytic viral therapies. In addition to my primary research focus, I established and currently oversee an active program in patient-derived xenograft development and characterization. Through this program I have developed a series of best practices for genetic characterization of human xenografts grown in mice and biomarker validation in PDX.

    Abstract:

    DATE: October 10, 2017
    TIME: 9:00AM PDT

    Patient-derived xenografts (PDX) are increasingly being used in biomedical research for therapeutic analysis in mice. Unlike traditional cell line xenografts, which are established from suspensions of cultured cells, PDX are maintained entirely in vivo. While exclusive in vivo maintenance is the primary advantage of PDX as a model for cancer, the practice introduces unique challenges and potential pitfalls to working with PDX as a model for cancer. Perhaps the most significant challenge to working with PDX is the need to disaggregate solid tumors prior to their use in downstream applications such as flow cytometry, immunomagnetic enrichment, single-cell sequencing or the establishment of cohorts for therapeutic trials. This webinar will discuss our experience with automated single cell dissociation of primary tumors and patient-derived xenografts as well as compatibility with downstream applications.

     

    Learning Objectives:

    • Advantages and challenges associate with using PDX models for cancer research
    • Solid tumor dissociation methods compatible for downstream single-cell applications, such as flow cytometry, immunomagnetic enrichment and single-cell sequencing

    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    Loading Comments...